5-氯-1,2-二氢吲唑-6-酮 | 116570-38-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 5-氯-1,2-二氢吲唑-6-酮
• 英文名称: 5-chloro-1H-indazol-6-ol
• 英文别名: 5-Chlor-6-hydroxy-indazol；5-chloro-1(2)H-indazol-6-ol；5-Chlor-1(2)H-indazol-6-ol
• CAS: 116570-38-8
• 化学式: C₇H₅ClN₂O
• 分子量: 168.583
• InChiKey: XPYRZGAZFOETTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-氯-1,2-二氢吲唑-6-酮 、 3-(chloromethyl-d₂)-5-methylisoxazole 在 caesium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 生成 3-(((5-chloro-1H-indazol-6-yl)oxy)methyl-d₂)-5-methylisoxazole
  参考文献：
  名称：

  INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF

  摘要：

  Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, R4, R5, R8, X and Y are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I). Also provided herein are methods of inhibiting SLC6A19 and methods of treating a SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.

  公开号：

  WO2024112831A1
• 作为产物：
  描述：

  6-溴-5-氯-1H-吲唑 在 copper(l) iodide 、 三溴化硼 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 5-氯-1,2-二氢吲唑-6-酮
  参考文献：
  名称：

  INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF

  摘要：

  Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, R4, R5, R8, X and Y are as defined elsewhere herein. Also provided herein are methods of preparing compounds of formula (I). Also provided herein are methods of inhibiting SLC6A19 and methods of treating a SLC6A19-mediated disease, disorder, or condition in an individual in need thereof.

  公开号：

  WO2024112831A1

文献信息

• Substituted fused pyrazole compounds and their use as LRRK2 inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10975081B2

  公开（公告）日：2021-04-13

  Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

  本发明公开了可抑制 LRRK2 激酶活性的取代融合吡唑（例如取代吲唑）、含有它们的药物组合物以及它们在帕金森病治疗中的用途。
• US2787515
  申请人：——

  公开号：——

  公开（公告）日：——